Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mifepristone - VGX Pharmaceuticals

Drug Profile

Mifepristone - VGX Pharmaceuticals

Alternative Names: PICTOVIR; VGX-410; VGX-410C

Latest Information Update: 15 Oct 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VGX Pharmaceuticals
  • Class Abortifacients; Antiprogestogens; Antivirals; Dimethylamines; Estrenes; Oral contraceptives; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists; Hepatitis C internal ribosome entry site inhibitors; HIV pre-integration complex translocation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 02 Sep 2007 VGX Pharmaceuticals completes enrolment in the VT003 trial for Hepatitis C virus infections in the US
  • 21 Feb 2007 VGX 410 licensed to VGX International to sell and market in Asia and other developing regions, including Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top